TY - JOUR
T1 - Airway-directed gene transfer of interleukin-10 using recombinant Sendai virus effectively prevents post-transplant fibrous airway obliteration in mice
AU - Shoji, F.
AU - Yonemitsu, Y.
AU - Okano, S.
AU - Yoshino, I.
AU - Nakagawa, K.
AU - Nakashima, Y.
AU - Hasegawa, M.
AU - Sugimachi, K.
AU - Sueishi, K.
PY - 2003/2
Y1 - 2003/2
N2 - Bronchiolitis obliterans (BO) after lung transplantation prevents a satisfactory prognosis, and recent studies suggested that interleukin-10 (IL-10) gene transfer to distant organs could inhibit BO in rodent models. Although delivery of the therapeutic gene to a local airway would be favored to minimize systemic effects, current limitations include lower gene transfer efficiency to airway epithelium. As recombinant Sendai virus (SeV) can produce dramatically efficient gene transfer to airway epithelium, we determined if SeV-mediated IL-10 gene transfer to the local airway would inhibit bronchial fibrous obliteration in murine tracheal allografts. Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA-versus CsA+=228 ± 78 versus 3627 ± 1372 pg/graft with 5 × 107 pfu), thereby suggesting the requirement of epithelia for efficient gene transfer. Even at the highest expression, no significant leakage of IL-10 was evident in the systemic circulation, and the induction of interferon-γ was completely diminished on day 7 by IL-10 gene transfer. As a result, luminal loss was significantly prevented in allografts treated with SeV-IL-10 (luminal opening, all control groups: 0% respectively, and SeV-IL-10 5 × 107 pfu: 25.7 ± 10.5%), an effect that was enhanced by short-term CsA treatment (SeV-IL-10 5 × 107 pfu with CsA: 63.7 ± 12.7%). We propose that SeV is a useful vector that can target airway epithelium to prevent BO avoiding putative systemic effect.
AB - Bronchiolitis obliterans (BO) after lung transplantation prevents a satisfactory prognosis, and recent studies suggested that interleukin-10 (IL-10) gene transfer to distant organs could inhibit BO in rodent models. Although delivery of the therapeutic gene to a local airway would be favored to minimize systemic effects, current limitations include lower gene transfer efficiency to airway epithelium. As recombinant Sendai virus (SeV) can produce dramatically efficient gene transfer to airway epithelium, we determined if SeV-mediated IL-10 gene transfer to the local airway would inhibit bronchial fibrous obliteration in murine tracheal allografts. Administration of cyclosporine A (CsA) significantly promoted not only recovery of the injured airway epithelium but also SeV-mediated IL-10 expression (CsA-versus CsA+=228 ± 78 versus 3627 ± 1372 pg/graft with 5 × 107 pfu), thereby suggesting the requirement of epithelia for efficient gene transfer. Even at the highest expression, no significant leakage of IL-10 was evident in the systemic circulation, and the induction of interferon-γ was completely diminished on day 7 by IL-10 gene transfer. As a result, luminal loss was significantly prevented in allografts treated with SeV-IL-10 (luminal opening, all control groups: 0% respectively, and SeV-IL-10 5 × 107 pfu: 25.7 ± 10.5%), an effect that was enhanced by short-term CsA treatment (SeV-IL-10 5 × 107 pfu with CsA: 63.7 ± 12.7%). We propose that SeV is a useful vector that can target airway epithelium to prevent BO avoiding putative systemic effect.
UR - http://www.scopus.com/inward/record.url?scp=0037322501&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037322501&partnerID=8YFLogxK
U2 - 10.1038/sj.gt.3301847
DO - 10.1038/sj.gt.3301847
M3 - Review article
C2 - 12571628
AN - SCOPUS:0037322501
SN - 0969-7128
VL - 10
SP - 213
EP - 218
JO - Gene Therapy
JF - Gene Therapy
IS - 3
ER -